Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
Healthcare
$11.43 +3.24%
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
52W Low $0.11High $3.87
Volume 0.24M
Average 19.76M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$171.27M
FY 2025 · Annual
Investing Cash Flow
$156.36M
FY 2025 · Annual
+438.7% YoYFinancing Cash Flow
$6.42M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 32.01M | 42.55M | 28.52M | 20.62M | 10.56M |
| Change in Working Capital | 774K | (4.46M) | (14.84M) | 39.46M | (13.63M) |
| Accounts Receivables | 0 | 0 | 0 | (5.34M) | (6.89M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.43M) | (1.81M) | 3.99M | (1.66M) | (2.75M) |
| Other Working Capital | 5.2M | (2.65M) | (18.83M) | 46.45M | (3.99M) |
| Other Non-Cash Items | 7.17M | (177K) | 2.6M | (11.17M) | 1.18M |
| Operating Cash Flow | (188.89M) | (187.03M) | (159.16M) | (3.47M) | (171.27M) |
| Capital Expenditures | (1.62M) | (475K) | 0 | 0 | (79K) |
| Acquisitions (Net) | 0 | (65K) | 0 | 0 | 0 |
| Purchases of Investments | (152.03M) | (238.06M) | (441.67M) | (494.78M) | (227.11M) |
| Sales of Investments | 36.23M | 237.5M | 330.7M | 523.8M | 383.54M |
| Other Investing Activities | (75K) | 65K | 0 | 0 | 0 |
| Investing Cash Flow | (117.43M) | (1.04M) | (110.97M) | 29.02M | 156.36M |
| Debt Repayment | 0 | (5.81M) | (11.61M) | (12.58M) | 0 |
| Common Stock Issued | 0 | 119.95M | 201.32M | 464K | 6.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 629K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.33M | 2.95M | 444K | 0 | 0 |
| Financing Cash Flow | 3.33M | 117.09M | 190.15M | (11.49M) | 6.43M |
| Effect of Forex Changes | (165K) | (517K) | 110K | (102K) | 141K |
| Net Change in Cash | (303.15M) | (71.49M) | (79.86M) | 13.97M | (8.34M) |
| Free Cash Flow | (190.51M) | (187.51M) | (159.16M) | (3.47M) | (171.35M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$170.4M
+ D&A$1.0M
+ Stock-Based Comp$10.6M
+ Deferred Tax$0
- Working Capital-$13.6M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$171.3M
- Capex-$79.0K
= Free Cash Flow-$171.3M
Analysis
FY2025 free cash flow is -$171.3M. FCF conversion is 100.6% of net income. Operating cash flow was -$171.3M, with capex of -$79.0K. The largest bridge item is Working Capital at -$13.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G | SC 13G filing | Nov 6, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 29, 2026 |
Does GOSS generate free cash flow?
Gossamer Bio, Inc. (GOSS) generated -$171.34M of free cash flow in fiscal 2025.
How much operating cash flow does GOSS produce?
Operating cash flow was -$171.27M, before capital expenditures of $79,000.00.
Continue the stock analysis
Jump to another research area for this company.